REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Glycoprotein (carbohydrate Containing) Glycoprotein (carbohydrate Containing)Glycoprotein (carbohydrate Containing) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.03/01/07 - 20070049520 - Method of using retro inverso peptides derived from leukemia inhibitory factor The invention provides methods of treatment using retro-inverso peptides derived from leukemia inhibitory factor (LIF) having between 18 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native LIF and ... 02/22/07 - 20070042942 - Glycopeptide carboxy-saccharide derivatives Disclosed are glycopeptide derivatives substituted at the C-terminus and/or the R-terminus with a substituent that comprises one or more saccharide groups and a carboxy group; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. ... 02/22/07 - 20070042941 - Galectin 9-inducing factors It has been disclosed that Galectin 9, which is a physiologically active substance acting as a lectin, is expressed in various cells and a correlationship is observed between the expression level of galectin 9 and the metastatic ability of tumors. Therefore, it is presumed that galectin 9 would relate to ... 02/15/07 - 20070037737 - Composition and method for the repair and regeneration of cartilage and other tissues The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere ... 02/15/07 - 20070037736 - Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. ... 02/15/07 - 20070037735 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C ... 02/08/07 - 20070032407 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are ... 02/08/07 - 20070032406 - Identification of novel nogo-receptors and methods related thereto Disclosed are compositions relating to the Nogo receptor (NgR) family as well as fragments, chimeras, and variants thereof. The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the NgRs as well as uses thereof. Such uses include modulation neurite outgrowth in a subject ... 02/08/07 - 20070032405 - Branched water-soluble polymers and their conjugates The present invention provides branched water-soluble polymers that allow two or more water-soluble polymers to be conjugated to another species. The branched polymers provide access to therapeutic agents that are conjugated at a single site to two or more water-soluble polymers. The branched polymers are based upon branch points that ... 02/01/07 - 20070027069 - Glucan-protein complex extracted from grifola (maitake) 1) a step of thermally extracting mycelia or fruit bodies of Grifola with water; 2) a step of adding alcohol to the obtained water-soluble extract fraction to a final concentration between 20% and 70% by volume, allowing the resulting solution to stand at a temperature between 1° C. and 25° ... 02/01/07 - 20070027068 - Erythropoietin: remodeling and glycoconjugation of erythropoietin The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. ... 01/25/07 - 20070021328 - Semi-synthetic rearranged vancomycin/desmethyl-vancomycin-based glycopeptides with antibiotic activity Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of a rearranged vancomycin or desmethyl-vancomycin scaffold, in particular, alkylation or acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this ... 01/11/07 - 20070010430 - Proteoglycan isolated from cartilaginous fish and process for producing the same There are provided a cartilage extract that can be effective even when taken in a small amount and has a clear mechanism of effective action and a method of producing the extract. Provided are an isolated proteoglycan which is derived from a water extract of cartilage of cartilaginous fish and ... 12/28/06 - 20060293222 - Methods of inducing ovulation The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ... 12/28/06 - 20060293221 - Mucosal repair by tff2 peptides The present invention relates to the use of trefoil factor 2 (TFF2) peptides and a pharmaceutical composition comprising TFF2 peptides for increasing the viscosity of mucin in mucus layers and the repair of damaged mucus layers in the gastrointestinal tract (mouth, oesophagus, stomach, small and large intestine, colon) the respiratory ... 12/21/06 - 20060287224 - Glycopegylated erythropoietin formulations The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified ... 12/21/06 - 20060287223 - Remodeling and glycoconjugation of peptides The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide. ... 12/07/06 - 20060276378 - Methods and pharmaceutical compositions for treating sepsis Methods and compositions for treating and preventing sepsis are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist in combination with an antibiotic agent. The invention further encompasses pharmaceutical compositions comprising a combination of an A1 adenosine receptor ... 12/07/06 - 20060276377 - Factor vii or viia polypeptide variants The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside ... 12/07/06 - 20060276376 - Increasing functional glycosylation of alpha-dystroglycan in the treatment of muscle degeneration Disclosed is a method for the prevention and/or treatment of muscle degeneration. In this method, a subject recognized as having muscle degeneration is treated with a composition effective to increase functional glycosylation of α-dystroglycan in an affected tissue in the subject. Functional glycosylation is to be increased to an extent ... 12/07/06 - 20060276375 - Gpi anchored glycoprotein aca as a novel tumor marker Described is a GPI-anchored surface glycoprotein having a GPI-anchor which is characterized by a non-acetylated inositol ring and diacyl glycerol as lipid tail of the anchor. A particular glycoprotein of the invention, ACA, is strongly expressed in melanoma cells, some leukemia cells and other tumor cells, thus, is an useful ... 11/16/06 - 20060258570 - Decorin proteoglycan inhibitor of fibrinogen blood clotting The present invention provides compositions and methods of inhibiting fibrin(ogen) clot formation by utilizing decorin proteoglycan as an anticoagulating and antithrombotic agent. The decorin proteoglycan comprises a decorin core protein or a fragment thereof covalently linked to a galactosaminoglycan polysaccharide. The decorin core protein acts as an anticoagulant and as ... 11/16/06 - 20060258569 - Compounds and methods for treating cancer The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an ... 11/16/06 - 20060258568 - Use of human chorionic gonadotropin in the treatment in the treatment of symptoms endometriosis The human chorionic gonadotropin is found to be a new, efficient agent for the treatment of symptoms like chronic pelvic pain, pre-menstrual syndrom, dysmenorrhea, dyspareunia and infertility, caused by endometriosis. ... 11/16/06 - 20060258567 - Xcrf polynucleotides and polypeptides and uses thereof The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. XCRF polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for ... 11/09/06 - 20060252672 - Protein n-glycosylation of eukaryotic cells using dolichol-linked oligosaccharide synthesis pathway, other n-gylosylation-increasing methods, and engineered hosts expressing products with increased n-glycosylation The level of glycosylation on products produced by a host (such as CHO cells, HEK cells and other mammalian cells, and non-mammalian cells) or patient can be increased by engineering, such as by supplying the host or patient with a gene sequence. For example, the host or patient can be ... 11/02/06 - 20060247155 - Methods for alleviating deleterious effects of 3-deoxyglucosone Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter ... 11/02/06 - 20060247154 - Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same A novel method for purifying various lectins is disclosed. More specifically a novel method for purifying Concanavalin A is set forth. Methods of expressing purifying and characterizing a mutant Concanavalin A, and sensors including the foregoing are also disclosed. ... 11/02/06 - 20060247153 - Method of improving learning and memory in mammals A method of improving learning and/or memory behavior in a mammal is described which involves administering to the mammal casein glycomacropeptide in an amount sufficient to improve learning and/or memory behavior in the mammal. ... 10/26/06 - 20060241025 - Biodegradable glucosamine-muramyl peptides for apoptosis modulation The present invention includes apoptosis modulating glucosamine-muramyl-peptides, obtained by specific endopeptidase digestion of gram positive bacteria, methods of preparation of thereof and medical food compositions for management and treatment of conditions caused by TNF alpha cytotoxicity. ... 10/26/06 - 20060241024 - Intermediate for preparing glycopeptide derivatives This invention provides 9-fluorenylmethoxycarbonyl compounds that are useful as intermediates for preparing glycopeptide antibiotics. ... 10/26/06 - 20060241023 - Methods for alleviating deleterious effects of 3-deoxyglucosone Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a recently discovered metabolic pathway. According to the normal functioning of this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter ... 10/26/06 - 20060241022 - Selectin targeting bioconjugates The present invention provides novel compositions comprising one or more selectin binding molecule covalently linked to a hydrophilic polymer, pharmaceutical compositions thereof, and methods for their use in treating anti-inflammatory disorders. ... 10/19/06 - 20060234918 - Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors Methods are provided for treating HPG axis-positive cancers, preventing or slowing proliferation of cells of HPG axis-positive cancer origin, preventing HPG axis-positive cancers in a patient at risk of contracting such cancers, preventing or inhibiting an upregulation of the cell cycle in HPG axis-positive cancer-derived cells in a patient, and ... 10/19/06 - 20060234917 - Truncated baff receptors The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders. ... 10/05/06 - 20060223744 - Prostate specific antigens and uses thereof wherein W1, W2, R1, R3, R4, R2A and R2B are as defined herein. In another aspect, the invention provides an antibody or antibody fragment which binds specifically to a normal or transformed PSA glycan or glycopeptide of the invention. ... 09/28/06 - 20060217293 - Coupling low-molecular substances to a modified polysaccharide The invention relates to a method for coupling low-molecular weight substances to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the low-molecular weight substance is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional ... 09/21/06 - 20060211605 - Mucosal repair by tff dimer peptides The present invention relates to the use of trefoil factor 1 (TFF1) and trefoil factor 3 (TFF3) dimers and a pharmaceutical composition comprising TFF dimers for increasing the viscosity of mucin in mucus layers and the repair of damaged mucus layers in the gastrointestinal tract (mouth, oesophagus, stomach, small and ... 09/21/06 - 20060211604 - Methods for treating inflammatory disorders using regulators of microvessel dilations The invention relates to methods for treating inflammatory diseases. Methods for analyzing microcirculation structural changes are also provided. ... 09/21/06 - 20060211603 - Ramoplanin derivatives possessing antibacterial activity Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed. ... 08/31/06 - 20060194718 - Method of using lectins for prevention and treatment of oral and alimentary tract disorders Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and ... 08/31/06 - 20060194717 - Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions. ... 08/31/06 - 20060194716 - Polyacid glycopeptide derivatives Disclosed are derivatives of glycopeptides that are substituted at the C-terminus with a substituent that comprises two or more (e.g. 2, 3, 4, or 5) carboxy (CO2H) groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. ... 08/31/06 - 20060194715 - Proteins encoded by ble genes and antibiotics from the bleomycin family The present invention provides use of a protein conjugate comprising a “ble” protein, which has specific binding properties. The protein conjugates are capable of binding reversibly to an antibiotic from the bleomycin family, which property is exploited in a variety of immobilisation methods. In preferred aspects of the invention, the ... 08/24/06 - 20060189517 - Cross-linked glycopeptide-cephalosporin antibiotics This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds. ... 08/24/06 - 20060189516 - Method for producing cross-linked hyaluronic acid-protein bio-composites This invention is concerned with a new method for producing cross-linked hyaluronic acid—protein bio-composites in various shapes. In the present process, a polysaccharide solution and a protein solution are mixed under moderate pH values in presence of salts to form a homogenous solution, which can be processed into various shapes, ... 08/24/06 - 20060189515 - Molecules for transporting a compound across the blood-brain barrier The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides. The present invention also relates to the use of these polypeptide for transporting a compound ... 08/24/06 - 20060189514 - Compositions and uses of a galectin for treatment of dry eye syndrome Methods for the therapeutic treatment of dry eye in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-1 protein, a galectin-3, a galectin-7 protein and/or a galectin-8 protein are provided. Pharmaceutical and ophthalmic compositions and kits, comprising a pharmaceutically an active ... 08/17/06 - 20060183672 - Glycoprotein hormone superagonists The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where ... 08/03/06 - 20060172925 - Thio-sirna aptamers The present invention includes thioaptamers that are partially thio-modified, methods and compositions for the isolation, selection, improvement, characterization and use of RNA and DNA thioaptamers for gene silencing, including degradative and non-degradative interference with translation. ... 07/27/06 - 20060166867 - Novel conjugates of polysaccharides and uses thereof Novel conjugates composed of a saccharide-containing moiety (e.g., aminoglycosides) covalently linked to a moiety containing two or more basic amino acid residues (e.g., a polyarginine) and processes of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses of these conjugates as antiviral and antibacterial agents. ... 07/13/06 - 20060154855 - Methods and compositions for beta conglycinin fraction of soy protein The present invention provides compositions and methods useful for preventing and/or treating a cardiovascular disorder such as atherosclerosis, coronary heart disease, myocardial infarction, and stroke in a subject, comprising administering to the subject an effective amount of β-conglycinin, with or without soy isoflavones. ... 07/06/06 - 20060148682 - Tumor-activated prodrug compounds and treatment The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm ... 07/06/06 - 20060148681 - Method for treating tumor and/or preventing tumor metastasis and relapse The present invention provides a method for treating tumor and/or preventing tumor metastasis and relapse comprising administrating a subject with a therapeutically effective amount of lectin capable of binding to the tumor and having tumor cytotoxicity and/or lymphocyte activation activity. ... 07/06/06 - 20060148680 - Glycoproteins produced in plants and methods of their use Methods of increasing the yield in plant expression of recombinant proteins comprising: engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) ... 07/06/06 - 20060148679 - Glycosolated enkephalin agents It is taught here that enkephalin peptides which are glycosylated with a disaccharide will be transported across the blood brain barrier and deliver analgesic effects superior to morphine when introduced into the bloodstream. Glycosylated peptides with disaccharides attached are superior to analogous peptides with either mono- or tri-saccharides attached. ... 06/29/06 - 20060142187 - Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity The present invention is based, at least in part, on the discovery that plasma C1INH contains a sialyl Lewisx related moiety on its N-glycan and is capable of binding selectin molecules. The invention provides methods for modulating cell-to-cell adhesion or cell migration comprising contacting a cell with a C1INH-type protein ... 06/29/06 - 20060142186 - Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer's disease Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease include administration of gonadotropin-releasing hormone analogues in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists. ... 06/29/06 - 20060142185 - Use of lupin conglutin for the treatment of type ii diabetes A method for the use of lupin conglutin gamma or of proteins showing homology higher than 50% with lupin conglutin gamma, for the preparation of a medicament, food supplements or foods for the treatment of type II diabetes, pharmaceutical and nutritional compositions containing lupin conglutin gamma, and the use of ... 06/22/06 - 20060135410 - Targeted delivery to legumain-expressing cells The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells. ... 06/15/06 - 20060128612 - Cross-linked glycopeptide-cephalosporin antibiotics This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds. ... 06/15/06 - 20060128611 - Composition for enzyme inhibition Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed. ... 06/15/06 - 20060128610 - Methods of treatment The inventions relate generally to methods for the prevention and treatment of conditions, diseases and disorders that would be improved, eased, or lessened by the administration of, for example, a composition comprising a therapeutically effective amount a glyponectin polypeptide, agonist, and/or nucleic acid constructs of the invention. ... 06/15/06 - 20060128609 - N¹- modified glycopeptides Described herein are N′-acylated derivatives of desleucylA82846B. The compounds are useful as antibacterial agents. ... 06/15/06 - 20060128608 - Novel chemical compounds and their use The present invention relates to prodrugs of pharmaceutical moieties, more specifically antimicrobial agents, methods for their preparation, pharmaceutical formulations containing them and their use in the treatment of microbial infections. ... 06/15/06 - 20060128607 - Method for inhibiting melanoma inhibitory activity mia The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA). ... 06/08/06 - 20060122102 - Methods and preparations for curing critically ill patients The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect ... 05/25/06 - 20060111279 - Glycopegylated erythropoietin The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified ... 05/25/06 - 20060111278 - Tff peptides A trefoil factor peptide. ... 05/18/06 - 20060105941 - Mixed antibiotic codrugs Novel compounds which degrade in vivo into two or more different active antibiotics are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. ... 05/11/06 - 20060100139 - Pharmaceutical used for treating hiv infection, the composition and uses thereof A fusion inhibitor used to treat HIV infection, has an amino acid sequence as follows: X-SWETWEREIENYTKQIYKILEESQEQQDRNEKDLLE-Z, wherein X is either an amino group or -X1-X2, wherein X1 is an imino group, and X2 is either an acetyl group, a hydrophobic group, or a macromolecular carrier group; Z is a carboxyl ... 05/11/06 - 20060100138 - Implantable collagen compositions The present invention relates to collagen compositions suitable for use in various tissue augmentation procedures. ... 05/04/06 - 20060094643 - Compositions of hyaluronic acid and methods of use The invention provides compositions for the treatment of disorders characterized by dryness including dry eye and dry mouth. The compositions commonly comprise a conjugate of hyaluronic acid and polylysine. These conjugates are attached to affected body tissues or surfaces using transglutaminase, and preferably endogenous transglutaminase. ... 04/20/06 - 20060084595 - Complex comprising ocif and polysaccharide A complex comprising at least one substance selected from the group consisting of an osteoclastogenesis inhibitory factor, an analogue thereof and a variant thereof, which is bound to at least one substance selected from the group consisting of a polysaccharide and a polysaccharide derivative. The complex has a prolonged retention ... 04/20/06 - 20060084594 - Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also ... 04/20/06 - 20060084593 - Anti-hiv composition, production method thereof and medicament The present invention relates to an anti-HIV composition and to the method for producing it. The composition of the present invention comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein. The polyanion may be chosen, for example, from the ... 04/13/06 - 20060079451 - Heparin-binding proteins modified with sugar chains, method of producing the same and pharmaceutical compositions containing same A heparin-binding protein functionalized by covalently bonding thereto a sugar chain, a method for producing the protein and a pharmaceutical composition containing the protein as an active ingredient, as well as a method of functionalizing a natural protein having no sugar chain by covalently bonding thereto a sugar chain. ... 04/13/06 - 20060079450 - Hydroxyethyl starch-containing polypeptide compositions The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures. ... 04/06/06 - 20060074014 - Dalbavancin compositions for treatment of bacterial infections The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A0, A1, B1, B2, C0, C1, isoB0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a ... 03/23/06 - 20060063707 - Compositions for enhancing memory and methods therefor Compositions for enhancing memory of a subject comprising a combination of a positive modulator of an AMPA receptor and a positive modulator of an NMDA receptor are provided, wherein each modulator of the combination is present at a subtherapeutic dose for effecting memory enhancement. Methods for using such compositions in ... 03/16/06 - 20060058225 - Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease The present invention provides methods of preventing and treating neural inflammatory or demyelinating disease, such as multiple sclerosis, via an inhibition of the activity or expression of phospholipase A2. The invention further relates to methods of identifying phospholipase A2 inhibitors and their use thereof for the prevention and/or treatment of ... 03/09/06 - 20060052288 - Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor A pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2 ... 02/23/06 - 20060040856 - Glycopegylated factor ix The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a ... 02/23/06 - 20060040855 - Low efficacy gonadotropin agonists and antagonists The present invention provides glycoprotein hormone analogs having partial agonist/antagonist activity comprising an α-subunit polypeptide and a β-subunit polypeptide. The analog lacks a naturally occurring oligosaccharide on α-subunit loop 2 and is cross-linked to the β-subunit by a disulfide bond. The present invention also provides a method for stimulating fertility ... 02/16/06 - 20060035818 - Use of corticotroph-derived glycoprotein hormone to induce lipolysis The use of corticotroph-derived glycoprotein hormone (CGH) to induce lipolysis, treat obesity, insulin resistance, and type II diabetes is described. ... 02/16/06 - 20060035817 - Use of galectin-3 and galectin-7 to promote the re-epithelialization of wounds Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 ... 02/16/06 - 20060035816 - Method and composition for inhibiting or slowing blood coagulation A method and composition for inhibiting or slowing blood coagulation includes lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a fragment of lactadherin. ... 02/09/06 - 20060030521 - Remodeling and glycoconjugation of peptides The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide. ... 02/09/06 - 20060030520 - Gdf3 propeptides and related methods In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with ... 02/02/06 - 20060025332 - Cross-linked glycopeptide-cephalosporin antibiotics This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds. ... 01/26/06 - 20060019882 - Use of yops as caspase inhibitor The present invention relates to the use of Yops as caspase inhibitors. More specifically, it relates to the use of YopE and YopT as inhibitors of caspase-1 activity. The inhibitor can be used to treat caspase-1-related pathologies, such as inflammatory diseases and to inhibit caspase-1-related and/or -mediated cell death. ... 01/26/06 - 20060019881 - Human spasmolytic polypeptide in glycosylated form or a functionally equivalent homologue thereof, characterized by being in glycosylated form. ... 01/26/06 - 20060019880 - Modulation of synaptogenesis Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain ... 01/26/06 - 20060019879 - Polynucleotide encoding autoantigens associated with endometriosis This invention provides a polynucleotide encoding Repro-EN-1.0 and IB1, polypeptides associated with endometriosis. Auto-antibodies against Repro-EN-1.0 and IB1 have been found in subjects diagnosed with endometriosis. This invention also provides methods of using this polynucleotide and polypeptide. ... 01/26/06 - 20060019878 - Polynucleotide encoding autoantigens associated with endometriosis This invention provides a polynucleotide encoding Repro-EN-1.0 and IB1, polypeptides associated with endometriosis. Auto-antibodies against Repro-EN-1.0 and IB1 have been found in subjects diagnosed with endometriosis. This invention also provides methods of using this polynucleotide and polypeptide. ... 01/26/06 - 20060019877 - Hasylated polypeptides The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO). ... 01/19/06 - 20060014673 - Kappa-a conopeptides and uses therefor The present invention is directed to kappaA (κA) conopeptides and the use of these peptides for blocking the flow of potassium ions through voltage-gated potassium channels. The κA conopeptides include unglycosylated and O-glycosylated peptides. ... 01/19/06 - 20060014672 - Tumor specific oligosaccharide epitopes and use thereof The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of ... 01/12/06 - 20060009378 - Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases Isolated polynucleotides encoding novel galectin-8 variants polypeptides are provided. Also provided are methods and kits using same for diagnosing prognosing and treating rheumatoid arthritis (RA) and other joint/chronic inflammatory diseases. ... 01/05/06 - 20060003925 - Methods of inducing ovulation The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ... 01/05/06 - 20060003924 - Sulfation-independent l-selectin or e-selectin ligand (hcell) and therapeutics thereof An isolated and purified glycoprotein and functional analogues thereof are disclosed. The glycoproteins are characterized by being expressed on at least primitive hematopoietic cells, and being a ligand for L-selectin. The binding activity of the ligand of the present invention to L-selectin is not sulfation-dependent and it is neither inhibited ... 12/29/05 - 20050288220 - Erythropoietin with high specific activity The invention concerns new EPO compositions with high specific activity which are characterized by a high proportion of N-acetyl-lactosamine units or/and tetraantennary branches in the carbohydrate structure. In addition the invention concerns a process for producing such EPO products. ... 12/29/05 - 20050288219 - Osteoprotegerin in milk The present invention pertains to osteoprotegerin obtainable from milk sources, in particular human and bovine milk. The present invention also relates to the use thereof for preparing an ingestible preparation and/or a pharmaceutical composition, in particular to the use of such a preparation/composition for preventing or treating disorders associated with ... 12/29/05 - 20050288218 - Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof The present invention is based, at least in part, on the discovery that the amino terminal domain and the N-linked carbohydrate contained in the amino terminal of C1INH are required for binding of C1INH to LPS. C1INH has the ability to block the binding of LPS to cells, e.g., macrophages. ... 12/22/05 - 20050282742 - Formulation of boronic acid compounds The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of ... 12/22/05 - 20050282741 - Peptides and their use to ameliorate cell death There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto. ... 12/15/05 - 20050277582 - Method for inactivating gonadotrophs Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, .alpha.-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and ... 12/15/05 - 20050277581 - Dalbavancin compositions for treatment of bacterial infections The invention provides methods and compositions for treatment of bacterial infections in adult and pediatric patients. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and skin structure. Dosing regimens include multiple dose administration of dalbavancin, ... 12/08/05 - 20050272643 - Removal of serum albumin from human serum or plasma A method of removing serum albumin from blood serum or plasma includes contacting the blood serum or plasma with a sugar-binding protein such as a lectin (e.g., Concanavalin A or wheat germ agglutinin) immobilized on an insoluble support such as a porous bead (e.g., agarose). The method may be practiced ... 12/01/05 - 20050267016 - Cd-10 activated prodrug compounds The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing ... 11/24/05 - 20050261172 - Agents and methods for promoting bone growth Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length ... 11/24/05 - 20050261171 - Combination cancer therapy The present invention relates to novel compositions comprising, (i) at least one of Taxol, Taxotere, bleomycin, carmustine, carboplatin, and doxorubicin; and (ii) MGd, a compound of Formula I. The present invention also relates to and methods of using said compositions to treat Cancer. ... 11/17/05 - 20050256036 - Gastrointestinal proliferative factor and uses thereof The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa. ... 11/17/05 - 20050256035 - Ctp-extended erythropoietin Erythropoietin containing a CTP extension and secreted from CHO cells exhibits a favorably extended biological half-life. ... 11/10/05 - 20050250679 - Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which does not comprise a naturally occurring amino acid and is covalently bonded to A and P in a regiospecific manner, and P represents a monomer, homopolymer ... 11/10/05 - 20050250678 - O-linked glycosylation of peptides The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue ... 11/10/05 - 20050250677 - Glycopeptide antibiotic derivatives Novel glycopeptide antibiotic derivatives, processes for their preparation, their use as a medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections are provided. The present invention relates to the use of glycopeptide antibiotics and their semisynthetic derivatives ... 11/03/05 - 20050245436 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons ... 10/27/05 - 20050239691 - Cross-linked glycopeptide - cephalosporin antibiotics This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds. ... 10/27/05 - 20050239690 - Intermediate for preparing glycopeptide derivatives where Ra, Rb, Y, Z and x are as defined, and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. ... 10/27/05 - 20050239689 - Vancomycin analogs and methods thereof The present invention provides vancomycin analogs and methods related to synthesis of these analogs via chemoenzymatic techniques. In a preferred embodiment, the vancomycin analogs have a structural moiety selected from the group consisting of: ... 10/27/05 - 20050239688 - Method for the synthesis of anthracycline-peptide conjugates The present invention relates to a method for the preparation of a compound of formula (I) or pharmaceutically acceptable salts thereof and intermediates thereof, comprising the steps of: a) halogenating a compound of formula (II), resulting in compound of formula (IIa), b) reacting a compound of formula (IIa) at its ... 10/20/05 - 20050233951 - Novel two gonadotropin releasing hormones and a method to isolate the same The present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid SEQ ID 1 as QHWSAWRLPG, and SEQ ID 2 QHWSWGILPG respectively, useful for induced breeding in fish both in combination and alone, by activating production of Gonadotropin, and a method of isolating ... 10/20/05 - 20050233950 - Synergistic antimicrobial compositions and methods for reducing biofilm formation The present invention provides novel compositions comprising: (a) a thiol-specific reagent and a cationic polypeptide or (b) a thiol-specific reagent and an iron-sequestering glyocoprotein; and uses thereof for the preparation of devices, and in particular medical devices, susceptible to colonization by biofilm forming bacteria. ... 10/20/05 - 20050233949 - Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof Disclosed are conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof, e.g. for treating or ameliorating hyperproliferative diseases. ... 10/06/05 - 20050222012 - Methods and compositions for treating leukemia A compound of the formula R1-Leu-A2-Val-A4-Ile-A6-Leu-A8-A9-A10-R2 SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, which disrupts the binding between the AF4 and AF9 proteins in mammalian cells in vitro and in vivo is useful in the treatment, prophylaxsis or diagnosis of various forms of leukemia. Such compounds are ... 10/06/05 - 20050222011 - Selectin ligands Podocalyxin like proteins (e.g. PCLP and PCLP-2) having selectin ligand activity are provided. Also provided are nucleic acid compositions encoding novel PCLP-2 proteins. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment ... 10/06/05 - 20050222010 - Composition for treating or preventing hyperuricemia A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout. ... 09/29/05 - 20050215465 - Methods of inducing il-10 production The invention provides a method of inducing IL-10 production ... 09/29/05 - 20050215464 - Binding agents for cd44 glycoproteins and methods of use The present invention is based on the finding that Gal-8 binds to carbohydrates of cell surface CD44std and CD44v and activates a chain of biological events within the cells. A specific effect exhibited was the induction of apoptosis in the CD44std and CD44v expressing cells. Thus, the present invention concerns ... 09/22/05 - 20050209133 - Glycoprotein synthesis Methods for making glycoproteins, both in vitro and in vivo, are provided. One method involves incorporating an unnatural amino acid into a protein and attaching one or more saccharide moieties to the unnatural amino acid. Another method involves incorporating an unnatural amino acid that includes a saccharide moiety into a ... 09/22/05 - 20050209132 - Cross-linked glycopeptide-cephalosporin antibiotics This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds. ... 09/15/05 - 20050203004 - Pharmacologically active polypeptide glycoconjugates Glycoconjugates of polypeptides pharmacologically active with a determined consensus sequence and physico-chemical stability, having an in vivo activity that is not characteristic of the isolated components, with pharmacological and clinical relevance, in terms of their immunomodulatory activity. They are prepared to this end for use in human and animal medicine. ... 09/15/05 - 20050203003 - Contulakin-g, analogs thereof and uses therefor The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a ... 09/08/05 - 20050197283 - Compositions containing beta 2-glycoprotein i for the prevention and/or treatment of vascular disease Methods and compositions employing beta2-glycoprotein-1 (β2GPI) or derivatives of β2GPI effective in inducing mucosal tolerance to atheroma related antigens, thus inhibiting inflammatory processes contributing to atheromatous vascular disease and sequalae, are provided. Also provided are articles of manufacture comprising mucosal tolerance inducing amounts of beta2-glycoprotein-1 46 (β2GPI) or derivatives thereof. ... 09/01/05 - 20050192211 - Fc-erythropoietin fusion protein with improved pharmacokinetics The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided. ... 08/25/05 - 20050187147 - Compositions and methods for increasing drug efficiency wherein D is a drug moiety; L, which may or may not be present, is a non-releasing linker moiety; and S is a substrate for a protein or lipid kinase that is overexpressed, overactive or exhibits undesired activity in a target system. ... 08/25/05 - 20050187146 - Biomaterials for enhanced healing The present invention relates to novel biomaterials and methods of using these new biomaterials to facilitate wound healing. The novel biomaterial may be a biocompatible polymer to which at least one bioactive polymer is covalently bonded by graft polymerization, copolymerization or cross-linking. Alternatively, the novel biomaterial may be a polymer ... 08/18/05 - 20050181987 - Compositions and methods for treatment of cancer Compositions containing one or more peptido-mimetics or modified peptido-mimetics of a carbohydrate ligand of an adhesion molecule in a physiologically acceptable carrier are useful for methods of reducing metastasis in a mammal and for inhibiting inflammatory response in a mammal. Particularly useful are embodiments in which the ligand is a ... 08/18/05 - 20050181986 - Method of treating disturbances of iron distribution in inflammatory intestinal diseases The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases. ... 08/18/05 - 20050181985 - Coupling proteins to a modified polysaccharide The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified ... 08/11/05 - 20050176627 - Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin Methods for increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous erythropoietin through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new chemically modified long acting erythropoietins, methods of producing the chemically modified long acting erythropoietins, and ... 08/11/05 - 20050176626 - Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist ... 08/04/05 - 20050171010 - Novel antibacterial agents Novel antibacterial agents that act as multibinding agents are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to a transglycosylase enzyme substrate thereby modulating the biological processes/functions thereof. ... 07/28/05 - 20050164919 - Polyacid glycopeptide derivatives Disclosed are derivatives of glycopeptides that are substituted at the C-terminus with a substituent that comprises two or more (e.g. 2, 3, 4, or 5) carboxy (CO2H) groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. ... 07/28/05 - 20050164918 - Segment of glycosylation-deficient hgfalpha-chain The present invention provides a segment of glycosylation-deficient HGF having mutation(s) introduced into an amino acid sequence so as to prevent glycosylation at at least one glycosylation site of a hepatocyte growth factor (HGF), and a method of producing the same. The segment of glycosylation-deficient HGF of the present invention ... 07/28/05 - 20050164917 - Methods and means for producing proteins with predetermined post-translational modifications Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in which the proteinaceous molecule is expressed. Preferably, the predetermined post-translational modifications include glycosylation. Also described are methods for obtaining ... 07/21/05 - 20050159344 - Glycopeptide carboxy-saccharide derivatives Disclosed are glycopeptide derivatives substituted at the C-terminus and/or the R-terminus with a substituent that comprises one or more saccharide groups and a carboxy group; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. ... 07/21/05 - 20050159343 - Inhibitors of glycosaminoglycans The present invention provides peptide derivatives with a specific affinity for glycosaminoglycan molecules. These peptide derivatives include multimers as well as chemically modified peptides and may be prepared by a variety of methods. The peptides of the invention have numerous functions, including but not limited to use as inhibitors of ... 07/21/05 - 20050159342 - Vancomycin haemostatic paste composition A haemostatic paste composition comprising powdered vancomycin mixed with a biocompatible carrier. The haemostatic paste composition is easily handled, adheres to a cut bone surface or an exposed bone surface, provides for effective haemostasis to prevent blood loss from a cut bone surface or an exposed bone surface, has no ... 07/21/05 - 20050159341 - Scaffolded maleimide clusters for multivalent peptide assembly Disclosed are scaffolded maleimide clusters, methods of making said clusters and use of said clusters as templates for multivalent peptide assembly. Multiple maleimide functionalities were introduced onto a scaffold molecule by the reaction of a core-centered polyamines with methoxycarbonylmaleimide or with activated esters of maleimide-containing compounds. The scaffolded maleimides allow ... 07/07/05 - 20050148499 - Compositions containing beta 2-glycoprotein i for the prevention and/or treatment of atherosclerosis A method for prevention and/or treatment of atherosclerosis in a subject, in need thereof is disclosed. The method is effected by orally administering to the subject an immunological oral tolerance-inducing composition which comprises an immunological oral tolerance-inducing amount of an active ingredient selected from the group consisting of beta2-glycoprotein-1 (β2GP-1) ... 07/07/05 - 20050148498 - Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same A composition comprising a hydrolyzed peptide extract of a lupin and a method of producing the same. ... 07/07/05 - 20050148497 - Method for administering glp-1 molecules The invention encompasses formulations that demonstrate the feasibility of oral absorption comprising GLP-1 compounds and specified delivery agents. ... 06/30/05 - 20050143292 - Glycopegylated erythropoietin The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified ... 06/30/05 - 20050143291 - Methods and compositions for modulating apoptosis This invention relates to compositions and methods for modulating apoptosis by regulating the activity of endoplasmic reticulum transmembrane glucose regulated protein 78 (GRP78). ... 06/23/05 - 20050137127 - Spatially-defined macrocyclic compounds useful for drug discovery Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a ... 06/23/05 - 20050137126 - Treatment of sars in individuals The present invention pertains to the use of subunits and oligomers of collectins and/or ficolins, such as mannan-binding lectin (MBL) in prophylactic and/or curative treatment of Severe Acute Respiratory Syndrome (SARS) in an individual. ... 06/16/05 - 20050130882 - Combination therapy including 9-nitro-20(s)-camptothecin A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation such as cancer and restenosis is provided. The method comprises: delivering to the patient a therapeutically effective amount of 9-nitro-20(S)-camptothecin in combination with an effective amount of an antimetabolite such as 5-fluorouracil. ... 06/16/05 - 20050130881 - Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals Single amino acid compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The single amino acid compounds may be used in compositions and methods to ... 06/09/05 - 20050124534 - Methods for treating conditions associated with the accumulation of excess extracellular matrix The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular ... 06/09/05 - 20050124533 - Glucocorticoid blocking agents for increasing blood-brain barrier permeability stan-261con Glucocorticoid blockers, including glucocorticoid receptor antagonists, are effective to prevent glucocorticoid-induced decrease in permeability of the blood-brain barrier and to increase the permeability of the blood-brain barrier. Administration of glucocorticoid blockers, including glucocorticoid receptor antagonists, concomitant with administration of drugs for treating diseases of the central nervous system increases delivery ... 06/02/05 - 20050119166 - Conjugates useful in the treatment of prostate cancer Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug ... 06/02/05 - 20050119165 - Vascular endothelial growth factor dimers This invention concerns novel vascular endothelial growth factor (VEGF) dimers, compositions containing such dimers, processes for making such dimers, and methods for the treatment of various diseases by administering such dimers or compositions. ... 06/02/05 - 20050119164 - Immunomodulatory polymeric antigens for treating inflammatory pathogies Provided are natural and synthetic immunomodulatory polymeric antigens (SPAs), compositions containing SPAs, and methods of using these natural and synthetic SPAs and compositions to prevent or treat inflammatory pathologies. ... ### FreshPatents.com Support |